Pricing

Xarelto Lawsuit Plaintiff Claims One-Size-Fits-All Dosage Is Ineffective

Download as PDF Single Release RSS Feed
Facebook Twitter Reddit LinkedIn Email

TheProductLawyers.com reports on Xarelto, approved in 2011 by the U.S. Food and Drug Administration (FDA). The drug's purpose is to impede strokes and blood clots for people suffering from a number of medical conditions or recovering from specific surgical procedures such as hip and knee replacement surgeries. An additional use of the blood thinner was added later to treat a common heart condition called atrial fibrillation. Since the drug's approval, it has become the subject of controversy. The FDA has given the drug two black box warnings which are the harshest warnings that a product can get before it is potentially removed completely from the consumer market.

Xarelto is manufactured by a subsidiary company of the Johnson and Johnson Corporation, Janssen Pharmaceuticals, as well as by Bayer AG. Since its release on the market, Xarelto, and its manufacturers have been the focus of thousands of lawsuits including 550 in Philadelphia, PA consolidated by the Court of Common Pleas, and over 2,800 others consolidated in a multidistrict litigation (MDL) in Eastern Louisiana assigned number 2592. In all of these cases up to this point, the plaintiffs have alleged that the drug causes sudden instances of uncontrollable bleeding. A new one, however, is notably different from the others in that it focuses on a new concern related to the marketed once-daily dosage regardless of the weight or size of the patient.

Xarelto is a once a day treatment, whereas, other blood thinners need to be taken twice daily. This new suit alleges that the once daily requirement is an ineffective amount. In this particular case, filed in October of 2015, the plaintiff suffered a stroke only 4 days after starting his treatment, as he was told he would be at risk of strokes due to his atrial fibrillation. He claims that not only did the drug not prevent his stroke he feels that Xarelto may have actually caused it.

The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.

Download as PDF Single Release RSS Feed
Facebook Twitter Reddit LinkedIn Email

About TheProductLawyers.com :

TheProductLawyers.com is a resource website sponsored by Banville Law to provide information on pending lawsuits against defective products, drugs and medical devices.

Contact TheProductLawyers.com:

Banville Law

165 West End Ave #1h,
New York, NY 10023

888-478-9711

Additional News Releases From TheProductLawyers.com:

November 30, 2016Research Indicates New Form Of Treating Ovarian Cancer As Talcum Powder Lawsuit Numbers Climb

November 30, 2016Parties in Talcum Powder Lawsuit In Missouri Exchange Briefings

November 30, 2016J&J Requests Disclosure Of Third Party Litigation Financing In Talcum Powder Lawsuit

November 30, 2016Delaware Sees 10 New Talcum Powder Lawsuit Filings

November 29, 2016Philadelphia Talcum Powder Lawsuit Filed Against Johnson & Johnson To Proceed

November 29, 2016Pennsboro Woman Files Talcum Powder Lawsuit On Behalf Of Her Deceased Mother

November 29, 2016Bioimaging Helps Early Detection Of Ovarian Cancer As Talcum Powder Lawsuit Filings Continue

November 28, 2016FDA Follow-Up: How Officials Have Responded To The Influx Of Talcum Powder Lawsuit Filings

November 28, 2016Talc Uses: A Look At The Product At The Center Of Talcum Powder Lawsuit Filings

November 28, 2016More Women Encouraged To File A Talcum Powder Lawsuit After Verdicts